
 
                                                 
                                                 
                                                 
                                                 
                                                 
                                                 
                                         
                                         
                                         
                                     
                                    
 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                             
                                             
                                             
                                                 
                                            Breast cancer remains the most common cancer and is one of the leading causes of cancer-related deaths in women worldwide. Approximately one in five patients with breast cancer are considered HER2-positive. HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors, and overexpression occurs due to HER2 gene amplification, which is often associated with aggressive disease and a poor prognosis in breast cancer.
This article will review the current treatment options and outline the latest developments of key experimental drugs for HER2-positive breast cancer with data sourced from IQVIA Pipeline Intelligence, a proprietary drug pipeline database.